PET Image Developments for HER2-Positive Breast Cancer

doi:10.7538/tws.2018.youxian.053

Abstract

Abstract:

Breast cancer is the most frequently diagnosed cancer among females worldwide. And overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is closely associated with poor prognosis. HER2 belongs to the epidermal growth factor receptor family of tyrosine kinases. It promotes a variety of cellular processes including cell growth, differentiation, cell survival, and cell adhesion and migration. Trastuzumab, which has been approved for the targeted therapy of HER2-positive breast cancer, is widely used now. Trastuzumab can downregulate ErbB2 receptors and cause antibody-dependent cell-mediated cytotoxicity. In clinical studies, simultaneous or sequential administration of trastuzumab with chemotherapy can significantly improve survival. However, its efficacy as a single drug has not yet reached the expected value, less than 30% of HER2-positive breast cancer patients have response to first-line trastuzumab treatment, and most of the initial responders eventually develop resistance to trastuzumab. Clinically, tumor size is assessed by imaging to evaluate trastuzumab treatment response, which is often delayed. Patients with high expression of HER2 may greatly benefit from trastuzumab, therefore, the success of HER2 targeted therapy depends on an accurate assessment of HER2 expression. At present, biopsy is routinely used to obtain pathological tissue for assessing HER2 status. However, with great disadvantages, biopsy is invasive and not suitable for repeated operations. In addition, tumor tissue is heterogeneous, as well as biopsy may not be able to reflect the HER2 status of distant metastases. Currently, compared with biopsy, positron emission tomography (PET), with a targeted HER2 probe, allows non-invasive, real-time assessment of whole body HER2 status. This technology will help physicians select patients who may benefit from HER2-targeted therapy and provide alternative treatment options for those who may not have response to it. Then it will save patients the cost and improve the prognosis of patients. Several antibodies and small molecules targeting HER2 have been labeled with different radionuclides for preclinical and clinical PET imaging studies. This review presents the latest advances in clinical molecular imaging using PET for selecting HER2-positive breast cancer.

Key words: breast cancer, human epidermal growth factor receptor-2 (HER2), positron emission tomography (PET), molecular probe

摘要：

乳腺癌是全世界女性发病率最高的癌症，患者中人表皮生长因子受体-2（HER2）的过表达与预后不良相关。HER2阳性乳腺癌首选曲妥珠单抗靶向治疗，曲妥珠单抗与化疗同步或序贯给药可以显著提高生存率。小于30%的HER2阳性乳腺癌患者对一线曲妥珠单抗治疗有效果，且大部分有效果患者最终会对曲妥珠单抗产生耐药性。HER2的高表达可能预测曲妥珠单抗的疗效，所以靶向治疗的成功取决于对HER2表达的准确评估。目前常规用穿刺活检获取病理组织评估HER2状态，但穿刺活检有创，不适于反复操作。此外肿瘤组织具有异质性，活检不一定能反映远处转移灶的HER2状态。与活检不同，使用靶向HER2探针的正电子发射断层扫描显像(PET)能无创、实时地评估全身HER2状态，有助于医师选择有效疗法并提供替代治疗方案。靶向HER2的抗体和小分子已用不同的放射性核素标记，用于临床前及临床PET显像研究。本文主要介绍靶向乳腺癌HER2 PET显像临床研究的最新进展，有助于医师了解分子影像在乳腺癌HER2诊疗研究中的临床结果，推进HER2 PET技术的临床转化。

关键词: 乳腺癌, 人表皮生长因子受体-2（HER2）, 正电子发射断层扫描显像（PET）, 分子探针

HUANG Qianhuan;XU Yuping;YANG Min. PET Image Developments for HER2-Positive Breast Cancer[J]. Journal of Isotopes, 2019, 32(6): 431-438.

黄钱焕;徐宇平;杨敏. 乳腺癌HER2的PET显像临床研究进展[J]. 同位素, 2019, 32(6): 431-438.

References

［1］Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012［J］. Ca-a Cancer Journal for Clinicians, 2015, 65(2): 87-108.
［2］Meric-Bernstam F, Hung M C. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy［J］. Clinical Cancer Research, 2006, 12(21): 6326-6330.
［3］Tagliabue E, Balsari A, Campiglio M, et al. HER2 as a target for breast cancer therapy［J］. Expert Opinion on Biological Therapy, 2010, 10(5): 711-724.
［4］Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond［J］. Expert Opinion on Pharmacotherapy, 2008, 9(15): 2583-2601.
［5］Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care［J］. Clinical Cancer Research, 2011, 17(7): 2055-2064.
［6］Mathenge E G, Dean C A, Clements D, et al. et al. Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model［J］. Neoplasia, 2014, 16(11): 950-960.
［7］Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease［J］. British Journal of Cancer, 2006, 17(2): 552-556.
［8］Gebhart G, Flamen P, De Vries E G, et al. Imaging diagnostic and therapeutic targets: human epidermal growth factor receptor 2［J］. Journal of Nuclear Medicine, 2016, 57(Suppl.1): 81S-88S.
［9］Haruka Y, Makoto T, Kazuhide H, et al. Dual-labeled near-infrared/^99mTc imaging probes using PAMAM-coated silica nanoparticles for the imaging of HER2-expressing cancer cells［J］. International Journal of Molecular Sciences, 2016, 17(7): 1086.
［10］Pectasides D, Gaglia A, Arapantoni-Dadioti P, et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy［J］. Anticancer Research, 2006, 26(1B): 647.
［11］Bose R, Kavuri S M, Searleman A C, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer［J］. Cancer Discovery, 2013, 3(2): 224.
［12］Jia Y, Chen L, Jia Q, et al. The well-accepted notion that gene amplification contributes to increased expression still remains, after all these years, a reasonable but unproven assumption［J］. Journal of Carcinogenesis, 2016, 15(1): 3.
［13］Massicano A V F, Marquez-Nostra B V, Lapi S E. Targeting HER2 in nuclear medicine for imaging and therapy［J］. Molecular Imaging, 2018, 17: 1-11.
［14］Goldstein R, Sosabowski J, Vigor K, et al. Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer［J］. Expert Review of Anticancer Therapy, 2013, 13(3): 359-373.
［15］Wooten A L, Madrid E, Schweitzer G D, et al. Routine production of ⁸⁹Zr using an automated module［J］. Applied Sciences, 2013, 3(3): 593-613.
［16］Wright B D, Lapi S E. Designing the magic bullet? The advancement of immuno-PET into clinical use［J］. Journal of Nuclear Medicine, 2013, 54(8): 1171.
［17］Dijkers E C, Oude Munnink T H, Kosterink J G, et al. Biodistribution of ⁸⁹Zr trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer［J］. Clinical Pharmacology & Therapeutics, 2010, 87(5): 586-592.
［18］Gaykema S B, Brouwers A H, Hovenga S, et al. Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer［J］. Journal of Clinical Oncology, 2012, 30(6): e74-e75.
［19］Ulaner G A, Hyman D M, Ross D S, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using ⁸⁹Zr-Trastuzumab PET/CT［J］. Journal of Nuclear Medicine, 2016, 57(10): 1523-1528.
［20］Ulaner G A, Hyman D M, Lyashchenko S K, et al. ⁸⁹Zr-Trastuzumab PET/CT for detection of human epidermal growth factor receptor 2-positive metastases in patients with human epidermal growth factor receptor 2-negative primary breast cancer［J］. Clinical Nuclear Medicine, 2017, 42(12): 1-6.
［21］Mortimer J E, Bading J R, Colcher D M, et al. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using ⁶⁴Cu-DOTA-trastuzumab PET［J］. Journal of Nuclear Medicine, 2014, 55(1): 23-29.
［22］Tamura K, Kurihara H, Yonemori K, et al. ⁶⁴Cu-DOTA-trastuzumab PET imaging in patients with HER2positive breast cancer［J］. Journal of Nuclear Medicine, 2013, 54(11): 1869-1875.
［23］Sasada S, Kurihara H, Kinoshita T, et al. Visualization of HER2specific breast cancer intratumoral heterogeneity using ⁶⁴Cu-DOTA-trastuzumab PET［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44(12): 2146-2147.
［24］Martinez V C, Fernandez-Morales L A, Oliveres H, et al. Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer［J］. Annals of Oncology, 2017, 28(8): 2027-2028.
［25］Spiridon C I, Guinn S, Vitetta E S. A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies［J］. Clinical Cancer Research, 2004, 10(10): 3542-3551.
［26］Beylergil V, Morris P G, Smith-Jones P M, et al. Pilot study of ⁶⁸Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer［J］. Nuclear Medicine Communications, 2013, 34(12): 1157.
［27］Nilsson J, Ståhl S, Lundeberg J, et al. Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins［J］. Protein Expression & Purification, 1997, 11(1): 1.
［28］Nygren P A. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold［J］. Febs Journal, 2008, 275(11): 2668-2676.
［29］Nord K, Nilsson J, Nilsson B, et al. A combinatorial library of an alpha-helical bacterial receptor domain［J］. Protein Engineering Design & Selection, 1995, 8(6): 601-608.
［30］Nord K, Gunneriusson E, Ringdahl J, et al. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain［J］. Nature Biotechnology, 1997, 15(8): 772-777.
［31］Orlova A, Magnusson M, Eriksson T L, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule［J］. Cancer Research, 2006, 66(8): 4339-4348.
［32］Orlova A, Tolmachev V, Pehrson R, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors［J］. Cancer Research, 2007, 67(5): 2178.
［33］Eigenbrot C, Ultsch M, Dubnovitsky A, et al. Structural basis for high-affinity HER2 receptor binding by an engineered protein［J］. Proceedings of the National Academy of Sciences, 2010, 107(34): 15039-15044.
［34］Sörensen J, Velikyan I, Sandberg D, et al. Measuring HER2-receptor expression in metastatic breast cancer using ［⁶⁸Ga］ ABY-025 affibody PET/CT［J］. Theranostics, 2016, 6(2): 262-271.
［35］Sandstrom M, Lindskog K, Velikyan I, et al. Biodistribution and radiation dosimetry of the anti HER2 affibody molecule ⁶⁸Ga-ABY-025 in breast cancer patients［J］. Journal of Nuclear Medicine, 2016, 57(6): 867-871.
［36］Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains［J］. Nature, 1993, 363(6 428): 446-448.
［37］Vaneycken I, D’huyvetter M, Hernot S, et al. Immuno-imaging using nanobodies［J］. Current Opinion in Biotechnology, 2011, 22(6): 877-881.
［38］Muyldermans S. Nanobodies: natural single domain antibodies［J］. Annual Review of Biochemistry, 2013, 82(82): 775-797.
［39］Keyaerts M, Xavier C, Heemskerk J, et al. Phase I study of ⁶⁸Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma［J］. Journal of Nuclear Medicine, 2016, 57(1): 27-33.

[1]	LI Zhongyong;CUI Haiping. Research Progress of Aβ Targeting PET Imaging Agents for Alzheimer’s Disease [J]. Journal of Isotopes, 2020, 33(1): 27-37.
[2]	LIU Bingnan;XIONG Liping;JIANG Shende;YAO Shaobo. Synthesis of 16-Epiestriol and its Radiolabeling Procedure [J]. Journal of Isotopes, 2018, 31(5): 283-290.
[3]	MA Jingxin;WU Zhou;JIANG Shende;WANG Hongliang;WU Zhifang. Synthesis and Biological Evaluation of 3-O-(2-¹⁸F-fluoroethyl)-L-DOPA as A Potential PET Agent for Tumor Imaging [J]. Journal of Isotopes, 2018, 31(5): 310-317.
[4]	TANG Ganghua. Compound Molecular Probe and Imaging [J]. Journal of Isotopes, 2018, 31(1): 48-56.
[5]	DAI Tiantian;WEI Qingyang. Advantages and Disadvantages of the Lutetium-176 Intrinsic Radiation in the PET System [J]. Journal of Isotopes, 2018, 31(1): 26-32.
[6]	LIU Yinli;LI Zhongyong. Preparation of ¹⁸F-Labeled Styryl Nitrogenous Heterocycles [J]. Journal of Isotopes, 2018, 31(1): 33-41.
[7]	WU Xiao-wei;ZHANG Xian-zhong. Research Progress of Radiopharmaceuticals for Progesterone Receptor Targeted Breast Cancer Imaging [J]. Journal of Isotopes, 2017, 30(1): 63-70.
[8]	YIN Ji-lin;WANG Cheng;WANG Xin-lu. PET Molecular Probes Targeting Folate Receptor [J]. Journal of Isotopes, 2016, 29(3): 184-192.
[9]	LI Xue-na;YIN Ya-fu;DU Bu-lin;LI Ya-ming. Effect of NOX 4 on the Invasion and Metastasis of Breast Cancer Cells with High Glucose Metabolism [J]. Journal of Isotopes, 2016, 29(2): 76-81.
[10]	WANG Rong-fu. Application Study on Isotope Tracing RRL Tumor Angiogenesis Imaging [J]. Journal of Isotopes, 2015, 28(4): 201-206.
[11]	JIA Li-na;ZHANG Lan. Application of ¹⁸F-Labeling Positron Molecular Probes in Tumor Receptor Imaging [J]. Journal of Isotopes, 2015, 28(2): 121-128.
[12]	HU Kong-zhen;WANG Hong-liang;TANG Gang-hua. Progress of the Methods for ¹⁸F-labeled Peptides [J]. Journal of Isotopes, 2012, 25(4): 243-252.
[13]	HUANG Ting-ting;WANG Hong-liang;TANG Gang-hua. Research Progress of Small-Molecule PET Probes for Apoptosis Imaging [J]. Journal of Isotopes, 2011, 24(4): 240-245.
[14]	. Application of PET in Alzheimer's Disease [J]. Journal of Isotopes, 2003, 16(1 ): 43-43 .
[15]	. RESEARCHING AND DEVELOPING OF ISOTOPE PRODUCTS IN U.S.A. [J]. Journal of Isotopes, 1990, 3 (1 ): 68-68 .